Companies all over 7MM are persistently working toward developing novel treatment therapies to address Thyroid eye disease. There are several promising drugs in the pipeline, which include VRDN-001 (Viridian Therapeutics), Secukinumab (Novartis), and IMVT-1401 (Immunovant Sciences GmbH), among others.
DelveInsight’s “Thyroid Eye Disease (TED) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Thyroid Eye Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Thyroid Eye Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Thyroid Eye Disease (TED): An Overview
Thyroid Eye Disease (TED) is a complex orbital inflammatory disease that can be sight-threatening, debilitating, and disfiguring. Thyroid Eye Disease is also known as Graves ophthalmopathy, named after Robert J. Graves, an Irish physician who first described thyrotoxicosis in a woman presenting with goiter, rapid heartbeat, and exophthalmos.
Thyroid Eye Disease affects eye muscles, eyelids, tear glands, and fatty tissues behind the eye to become inflamed. This can cause the eyes and eyelids to become red, swollen, and uncomfortable, and the eyes can be pushed forward (‘staring’ or ‘bulging’ eyes)
Thyroid Eye Disease (TED) Market Key Facts
According to a study by Bahn et al. (2019), in approximately 40% of patients with Thyroid Eye Disease, the ocular and systemic symptoms have simultaneous onset.
According to NORD, the exact prevalence (i.e., the number of people who have a disorder in a specific population at a specific time) of thyroid eye disease is not known but is estimated to be 16 per 100,000 women in the general population, and 2.9 per 100,000 men in the general population.
According to Karla et al. (2020), the global prevalence of patients with thyroid eye disease was 10.36% for hypothyroidism, 7.9% for euthyroidism, and 86.2% for hyperthyroidism.
The major drivers of the Graves disease market are the rise in the number of patients with thyroid disorders, favorable reimbursement policies for treatment, and an increase in awareness about the complications associated with thyroid disorders. Increasing iodine disorder and thyroid tumor screening are among the leading factors fueling the market’s growth.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Thyroid Eye Disease market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Thyroid Eye Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Thyroid Eye Disease (TED) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Thyroid Eye Disease (TED) Epidemiology, Segmented by –
Severity-Specific Cases of Thyroid Eye Disease in 7MM (2019-32)
Diagnosed and treatable cases of Thyroid Eye Disease in 7MM (2019-32)
Gender-specific cases of Thyroid Eye Disease in 7MM (2019-32)
Age-specific cases of Thyroid Eye Disease in 7MM (2019-32)
Total Prevalent cases of Thyroid Eye Disease in 7MM (2019-32)
Thyroid Eye Disease (TED) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Thyroid Eye Disease market or expected to be launched during the study period. The analysis covers the Thyroid Eye Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Thyroid Eye Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Thyroid Eye Disease Market Will Evolve and Grow by 2032 @
Thyroid Eye Disease (TED) Therapeutics Analysis
The Leading Companies in the Thyroid Eye Disease (TED) Therapeutics Market Include:
Immunovant Sciences GmbH
And Many Others
Thyroid Eye Disease (TED) Therapies Covered in the Report Include:
VRDN—001 (Viridian Therapeutics)
Secukinumab (Novartis), and
IMVT-1401 (Immunovant Sciences GmbH)
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Thyroid Eye Disease Competitive Intelligence Analysis
4. Thyroid Eye Disease Market Overview at a Glance
5. Thyroid Eye Disease Disease Background and Overview
6. Thyroid Eye Disease Patient Journey
7. Thyroid Eye Disease Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Thyroid Eye Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Thyroid Eye Disease Unmet Needs
10. Key Endpoints of Thyroid Eye Disease Treatment
11. Thyroid Eye Disease Marketed Products
12. Thyroid Eye Disease Emerging Drugs and Latest Therapeutic Advances
13. Thyroid Eye Disease Seven Major Market Analysis
14. Attribute Analysis
15. Thyroid Eye Disease Market Outlook (In US, EU5, and Japan)
16. Thyroid Eye Disease Access and Reimbursement Overview
17. KOL Views on the Thyroid Eye Disease Market
18. Thyroid Eye Disease Market Drivers
19. Thyroid Eye Disease Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Other Trending Healthcare Reports By DelveInsight
The global Personal Emergency Response Systems (PERS)/Medical Alert Systems Market was valued at USD 6,602.01 million in 2021, growing at a CAGR of 9.60% during the forecast period from 2022 to 2027 to reach USD 11,425.98 million by 2027. The market is witnessing positive growth owing to various factors such as a rise in the geriatric population, an increase in the prevalence of falls in older adults, the surge in PERS or medical alert system products launched, increasing prevalence of chronic diseases such as Alzheimer’s disease (AD), and improvements in healthcare infrastructure facilities across the globe.
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States